To order this detailed 350+ page report, please visit this link Key InclusionsA detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory),  type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both).A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, type of target, target indication(s), target therapeutic area(s), enrolled patients population and regional distribution.Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations.In addition, each profile includes an informed future outlook.An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, in the period between 2016 and 2019 (till November), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, popular target immune checkpoints, responsible study section, focus area, prominent program officers, and type of recipient organizations.It also features a detailed analysis based on the types of target immune checkpoints and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as grant amount, support period, type of grant application and number of disease indications under investigation.An analysis of the partnerships that have been established in the recent past, covering R collaborations, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant types of deals.An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for next generation immune checkpoint therapy development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of grants and number of publications [B] a five-dimensional spider-web analysis, highlighting the most popular immune checkpoint targets.An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of therapies under development, target disease indications, partnership activity and target portfolio.Informed estimates of the existing market size and the future opportunity for next generation immune checkpoint inhibitors and stimulators, over the next decade.Based on multiple parameters, such as disease prevalence, anticipated adoption of next generation checkpoint modulator therapies and their likely selling price, we have provided informed estimates on the evolution of the market for the period 2020-2030.
1
Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development.Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this link The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:Target Disease Indication Breast CancerChronic Lymphocytic LeukemiaColorectal CancerHead and Neck CancerLung CancerLupus NephritisMelanomaMultiple MyelomaPrimary Sjögren's SyndromeOthers  Target Immune CheckpointB7-H3CD38CD40CD47Others Mechanism of ActionInhibitoryStimulatory Therapeutic ModalityMonoclonal AntibodySmall Molecule Type of Therapy Monotherapy Combination Therapy Route of AdministrationIntravenousSubcutaneousOthers Key Geographical Regions North AmericaEuropeAsia-Pacific and the Rest of the World  The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: Bristol Myers SquibbGlaxoSmithKlineIncyteNovartisTrillium Therapeutics Table of Contents  Preface 2.Executive Summary Introduction Current Market Landscape: Clinical and Preclinical Molecules Market Landscape: Therapies Targeting Cd47 Market Landscape: Therapies Targeting 4-1bb Clinical Trial Analysis Company Profiles: Next Generation Inhibitors and Stimulators Academic Grants Analysis Partnerships and Collaborations Target Competitiveness Analysis Big Pharma Initiatives Market Forecast and Opportunity Analysis Concluding Remarks  Executive Insights  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]   
1
Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly.Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics.Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this link The USD 9.3 billion (by 2030) financial opportunity within the microbial biomanufacturing market has been analyzed across the following segments:Type of ProductAPIFDF Type of BiologicProteinsEnzymesGrowth HormonesAntibody based DrugsOthers (plasmid DNA, probiotics, microbiome-based biologics) Type of Microbial Expression SystemBacteriaYeastOthers (Algae and fungi) Scale of OperationCommercialPreclinical / Clinical Type of End UserSmall CompaniesMid-sized CompaniesLarge / Very Large Companies Key Geographical RegionsNorth AmericaEuropeAsia PacificMiddle East and North AfricaLatin America The Microbial Contract Biomanufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: AGC BiologicsAldevronBioVectraEirGenixEtinproEurogentecNorthway BiotechpharmaOlogy BioservicesPorton BiopharmaStelis Biopharma Table of Contents  Preface 2.Executive Summary Introduction Market Landscape Company Competitiveness Analysis  Company Profiles  Recent Partnerships Recent Expansions Microbial fermentation technology platforms Assessment of Relative Competition and Growth Make versus Buy Decision Making Framework  Big Pharma Initiatives in Microbial Biomanufacturing  Case study: comparison of small molecule and large   Market Sizing and Opportunity Analysis Impact of covid-19 pandemic on microbial contract biomanufacturing market  Swot Analysis   Conclusion Appendix 3: List of Companies and Organizations Interview Transcripts  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]  
 To order this detailed 310+ page report, please visit this link  Key Inclusions A detailed assessment of the current market landscape of therapeutics targeting STING pathway, based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), phase of development (discovery, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first line or greater).The chapter also features an analysis of the developer landscape (including information on year of establishment, company size, geography and most active players).Further the chapter includes an analysis on the clinical trials focused on STING, along with information on parameters, such as recruitment status, study design and clinical endpoints.A detailed chapter highlighting various technology platforms that are being actively used for the development of STING modulators and analysis based on several parameters, such as type of modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides), and analysis based on technology developer landscape (including information on year of establishment, company size and geography).Elaborate profiles of key players that are engaged in the development of therapeutics targeting STING pathway (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, recent developments and an informed future outlook.Additionally, each drug profile features information on the type of drug, route of administration, target indications and current status of development.Tabulated profiles of industry players (shortlisted on the basis of the antagonist in pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, key members of the executive team and recent developments), along with descriptions of their respective drug candidates.A study on various grants that have been awarded to research institutes engaged in projects related to STING pathway, during the period 2015 - Q1 2020, based on multiple parameters, such as number of grants awarded, amount awarded, funding institute, support period, funding mechanism, type of grant application, grant activity code, most popular NIH department, type of recipient organization, regional distribution, most popular recipient organization(s), prominent project leader(s) and study section.It also includes an analysis of on grant attractiveness.An analysis of big pharma players engaged in the development of therapeutics targeting STING pathway, based on several parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area(s), type of therapy and route of administration.In addition, the chapter features a benchmarking analysis of the aforementioned players.An analysis of the start-ups / small players (established in the last ten years, less than 50 employees) engaged in the development of therapeutics targeting STING pathway, based on several relevant parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area, funding received, number of investors, type of funding, partnership activity, number of patents filed, grants received, and start-up health indexing.A detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 - Q1 2020, highlighting the research focus within the industry.
PEGylated Drugs Market is expected to register a CAGR of 5.53% to reach USD 13,503.67 Million by 2025.PEGylation refers to the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to bioactive molecules (proteins, peptides, enzymes, antibody fragments, oligonucleotides, etc.).It is a promising technique to increase the therapeutic efficacy of medicines in clinical settings.Dapirolizumab pegol is an anti-CD40L pegylated Fab and is in Phase 2b of the clinical trial.The drug is being developed for the treatment of systemic lupus erythematosus.Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8436 However, adverse reactions associated with PEGylated drugs and drug recalls are anticipated to restrain the growth of the global PEGylated drugs market during the forecast period.Market DynamicsThe Global PEGylated Drugs Market is emerging due to the increase in the prevalence of chronic diseases such as cancer, growing pharmaceutical industry, and advancements in the biologics sector.For instance, according to the National Cancer Institute, in 2016, 15.5 million new cases of cancer were registered, and approximately USD 147.3 billion were spent for cancer care in the US.The use of advanced drug delivery system with PEGylation technology is significant in the field of anti-cancer therapy as PEGylating enhances retention time of therapeutics which in turn is expected to boost the growth of the global PEGylated drugs market.SegmentationThe Global PEGylated Drugs Market has been segmented into molecule, indication, and region.On the basis of molecule, the global PEGylated drugs market has been segmented into protein, enzyme, aptamer, antigen-binding fragment (FAB’ fragment) and others.
Summary – A New Market Study, “Global Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Region: Trend Forecast and Growth Opportunity” Has Been Featured On Wiseguyreports.Global artificial intelligence (AI) in drug discovery market will reach $2.57 billion by 2026, growing by 30.3% annually over 2020-2026 despite the COVID-19 impact.Highlighted with 86 tables and 86 figures, this 178-page report “Global Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global AI in drug discovery market and all its sub-segments through extensively detailed classifications.Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.The report provides historical market data for 2015-2019, revenue estimates for 2020, and forecasts from 2021 till 2026.(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)Also Read : https://www.benzinga.com/pressreleases/20/06/ab16160457/global-artificial-intelligence-ai-in-drug-discovery-market-2020-latest-trends-share-opportunitiesIn-depth qualitative analyses include identification and investigation of the following aspects:Market StructureGrowth DriversRestraints and ChallengesEmerging Product Trends & Market OpportunitiesPorter’s Fiver ForcesThe trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19.The balanced (most likely) projection is used to quantify global AI in drug discovery market in every aspect of the classification from perspectives of Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Region.Based on offering, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.SoftwareServiceBased on technology, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.Deep LearningSupervised LearningReinforcement LearningUnsupervised LearningOther TechnologiesBased on drug type, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.Large-molecule DrugsSmall-molecular DrugsBased on therapeutic area, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.OncologyNeurodegenerative DiseasesCardiovascular DiseaseMetabolic DiseasesOther Therapeutic AreasBased on application, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.Information & Data AnalysisDrug DesignDrug EvaluationClinical TrialsOther ApplicationsBased on end user, the global market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.Pharmaceutical & Biotechnology CompaniesAcademic & Research InstitutesContract Research OrganizationsGeographically, the following regions together with the listed national/local markets are fully investigated:APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)North America (U.S., Canada, and Mexico)South America (Brazil, Chile, Argentina, Rest of South America)RoW (Saudi Arabia, UAE, Egypt)For each of the aforementioned regions and countries, detailed analysis and data for annual revenue are available for 2015-2026.
Peptide mapping is based on the molecular weight of proteins and peptides and the characteristics of amino acid composition, using specific proteolytic enzymesto act on specialpeptide chain site.Reversed-phase high performance liquid chromatography has become a standard method for protein analysis and characterization, especially for the analysis and characterization of therapeutic drugs.Reversed-phase chromatography has high resolution and good detection sensitivity, and can provide a lot of information about proteins.Sometimes, protein is analyzed as a complete molecule, but more often, proteolytic enzymes are used to act on special amino acid residues to break the carbon backbone, thereby breaking the protein into small fragments.Subsequently, reversed-phase high performance liquid chromatography was used to analyze the peptide fragments produced by the cleavage.This technique is called peptide map analysis and is a standard protein analysis method.A large amount of information about the protein can be obtained by analyzing the peptide fragment after the protein cleavage by reversed-phase chromatography.By comparing the peptide map of the expressed protein with the reference standard protein, the purity of the protein and the accuracy of expression can be obtained.Peptide mapping is usually used as a tool for identification and analysis of protein therapeutics.Peptide maps can be used to identify protein degradation products, such as asparagine and oxidized methionine that undergo deamidation.Peptide map can confirm or verify the disulfide bond connection, so as to obtain the tertiary structure and therapeutic effect of protein.The peptide map can determine the glycosylation (adding carbohydrates) site, providing conditions for detailed identification of the oligosaccharides attached to it.The peptide map obtained by mass spectrometry provides an advanced method for protein identification, peptide sequence analysis and data confirmation.In biological proteome research, protease hydrolysates are also used for protein identification and quantitative analysis.transsexual.Disulfide bonds prevent complete denaturation of the protein.The disulfide bond can usually be reduced by adding a reducing agent such as dithiothreitol (DTT) at a concentration of ~20 mM during the denaturation process of the protein to be hydrolyzed.Carboxymethylation of free cysteine.When urea or guanidine salt is present in the solution, the hydrolysis reaction cannot proceed because trypsin itself, as a protein, will denature and lose its enzymatic activity.Urea or guanidine salt must be removed by ion exchange or dialysis or the concentration must be reduced to below 1M.Trypsin hydrolysis.At 37°C, hydrolysis can be completed within 1 to 4 hours, depending on the protein.If the time, temperature or relative concentration of trypsin is too low, the hydrolysis will be incomplete, and some potential cleavage may not occur, eventually leading to the formation of macromolecular peptides containing lysine or arginine.If the hydrolysis time, temperature, or concentration of trypsin are too high, trypsin will dissolve itself and produce "autolysates", that is, peptides produced by trypsin hydrolysis, which will cause confusion.The usual practice is to ignore protein and consider trypsin.Perform chromatographic analysis on the obtained sample under the condition of complete protein hydrolysis to understand the degree of trypsin autolysis and the position of any trypsin autolysis peptide product in the peptide map.During the development of the trypsin hydrolysis protocol, the hydrolysis time, temperature and relative concentration of trypsin and protein were optimized.When using peptide maps to determine the location of disulfide bonds, the protein must be hydrolyzed without reducing the disulfide bonds.
Summary - A new market study, titled “Global Beta Carotene Market Data Survey Report 2013-2025” has been featured on WiseGuyReports.Beta carotene is an orange lipophilic terpenoid pigment found in plants and fruits.And it is a provitamin of vitamin A, meaning it is transformed to active vitamin A in the body.Beta carotene powder is a member of the carotenes, and it is distinguished by having beta-rings at both ends of the molecule.Beta carotene is the most common form of carotene in plants.ALSO READ: https://icrowdnewswire.com/2019/07/11/beta-carotene-market-global-key-players-trends-share-industry-size-growth-opportunities-forecast-to-2024/ The global Beta Carotene market will reach xxx Million USD in 2019 with CAGR xx% 2019-2025.
Summary - A new market study, titled “Global Isomaltulose Market Professional Survey Report 2019” has been featured on WiseGuyReports.Isomaltulose is a sucrose isomer, is a reducing disaccharide, composed of a fructose and glucose molecule joined together by a 1, 6- glycosidic bond.Isomaltulose occurs at low levels in honey as well as in sugar cane and sugar beet extract naturally.The global isomaltulose market driving factor is the increasing demand for non-carcinogenic sugar for the manufacture of food and healthcare products.Isomaltulose is extensively used for the production of food products such as candies, chocolates, cereals, sports and energy drinks along with health supplements.ALSO READ: https://icrowdnewswire.com/2019/11/06/isomaltulose-market-segmentation-application-technology-market-analysis-research-report-2025/ The global Isomaltulose market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.This report focuses on Isomaltulose volume and value at global level, regional level and company level.From a global perspective, this report represents overall Isomaltulose market size by analyzing historical data and future prospect.Regionally, this report categorizes the production, apparent consumption, export and import of Isomaltulose in North America, Europe, China, Japan, Southeast Asia and India.For each manufacturer covered, this report analyzes their Isomaltulose manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
G-protein coupled receptors (GPCRs) market Utilization of the G protein-coupled receptors in modern pharmacology market for the discovery of various drugs related to as cardiovascular diseases; breast cancer etc.is defined as G protein-coupled receptors market.G protein-coupled receptors (GPCRs) also known by other name such as seven-(pass)-transmembrane domain receptors detect molecule outside the cell by the large protein family of receptors.It activates an internal signal transduction pathway for cell responses.Coupled with the G proteins, they are passed through cell membrane for seven times and therefore it is also known as seven-transmembrane receptors.G-protein coupled receptors (GPCRs) market is expected to register a substantial CAGR of 9.3% in the forecast period of 2019-2026.This rise in the market can be attributed to the increasing health problems such as cardiovascular diseases, advancement in technology of cryotherapy equipment and high application in research and development for newer drugs.Get a Sample Copy of Global G-Protein Coupled Receptors (GPCRs) Market Report to Understand the Complete Insights @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-g-protein-coupled-receptors-gpcrs-marketMarket Drivers and Restraints:Increasing health problems such as cardiovascular diseases, breast cancer and respiratory disordersHigh application in research and development for innovative drugsIncrease in the investment by the government for research and development of drug targets, biosensors, orphan drug receptorsAdvancement in technology of cryotherapy equipmentCryogenic gases have cryogenic effects on healthCryotherapy involves complex mechanismsStringent regulations and norms by the governmental bodiesThe major players covered in the G-Protein Coupled Receptors (GPCRs) Market Few of the major market competitors currently working in the global G-protein coupled receptors (GPCRs) market are QIAGEN, Merck KGaA, HD Biosciences Co. Ltd, Cisbio Bioassays, Enzo Life Sciences Inc., Eurofins DiscoverX Corporation, Promega Corporation, PerkinElmer Inc., Abcam plc, Thermo Fisher Scientific Inc, BD, Actelion Pharmaceuticals Ltd, Accure Pharma, Anchor Therapeutics, Arena Pharmaceuticals Inc., ADDEX THERAPEUTICS and others.Major TOC Of The ReportChapter One:  G-Protein Coupled Receptors (GPCRs) Market OverviewChapter Two: Manufacturers ProfilesChapter Three:  Global G-Protein Coupled Receptors (GPCRs) Market  Competition, by PlayersChapter Four: Global G-Protein Coupled Receptors (GPCRs) Market Size by RegionsChapter Five: North America G-Protein Coupled Receptors (GPCRs) Market Revenue by CountriesChapter Six: Europe G-Protein Coupled Receptors (GPCRs) Market Revenue by CountriesChapter Seven: Asia-Pacific G-Protein Coupled Receptors (GPCRs) Market Revenue by CountriesChapter Eight: South America G-Protein Coupled Receptors (GPCRs) Market Revenue by CountriesNew Business Strategies, Challenges & Policies are mentioned in Table of Content, Request Detailed TOC at @https://www.databridgemarketresearch.com/toc/?dbmr=global-g-protein-coupled-receptors-gpcrs-marketKey Report HighlightsComprehensive pricing analysis based on different product types and regional segmentsMarket size data in terms of revenue and sales volumeDeep insights about regulatory and investment scenarios of the global G-Protein Coupled Receptors (GPCRs) Market    Analysis of market effect factors and their impact on the forecast and outlook of the global G-Protein Coupled Receptors (GPCRs) Market    The detailed assessment of the vendor landscape and leading companies to help understand the level of competition in the global G-Protein Coupled Receptors (GPCRs) Market    A roadmap of growth opportunities available in the global G-Protein Coupled Receptors (GPCRs) Market    with the identification of key factorsThe exhaustive analysis of various trends of the global G-Protein Coupled Receptors (GPCRs) Market    to help identify market developmentsInsightful Details Available @https://www.databridgemarketresearch.com/reports/global-g-protein-coupled-receptors-gpcrs-marketKey Questions Answered in Report:What is the key to the G-Protein Coupled Receptors (GPCRs) Market?What will the G-Protein Coupled Receptors (GPCRs) Market Demand and what will be Growth?What are the latest opportunities for G-Protein Coupled Receptors (GPCRs) Market in the future?What are the strengths of the key players?About Us:Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.
3
To order this detailed 290+ page report, please visit this link Key InclusionsA detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules, including information on year of establishment, company size, location of headquarters, type of business model used (contract service providers (CROs), software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, antibody drug conjugates (ADCs), antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors and nucleic acids), type of in silico approach used (structure-based drug design (SBDD), fragment-based drug design (FBDD), target-based drug design (TBDD), ligand-based drug design (LBDD) and interface-based drug design (IBDD)), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes).Insights on contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of location of their company size (small (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services, featuring a brief overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio) and an informed future outlook.A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters, such as the experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services offered and number of large molecules, for which the aforementioned services are offered.A detailed analysis assessing the current opportunity within in silico drug discovery services market, comparing the number of pipeline products and current market size across different types of large molecules, and the availability and capabilities of affiliated in silico drug discovery service providers.A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.A case study comparing the key challenges associated with the discovery and production of large molecules, affiliated product development timelines, and manufacturing protocols, with those of small molecule drugs.Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in providing in silico services for discovery of large molecule drugs.A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery purposes and are likely to impact early stage research over the coming years.A case study highlighting several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: Key Drug Discovery StepsTarget IdentificationTarget ValidationHit GenerationHit-to-LeadLead Optimization Type of Large MoleculeAntibodiesProteinsPeptidesNucleic AcidsVectors Company SizeSmallMid-sizedLarge Target therapeutic AreaAutoimmune DisordersBlood DisordersCardiovascular DisordersGastrointestinal and Digestive DisordersHormonal DisordersHuman Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)Infectious DiseasesMetabolic DisordersMental DisordersMusculoskeletal DisordersNeurological DisordersOncological DisordersRespiratory DisordersSkin DisordersUrogenital DisordersOthers Type of SponsorIndustry PlayersNon-Industry Players Key Geographical RegionsNorth AmericaEuropeAsia-Pacific The report includes detailed transcripts of discussions held with the following experts:John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals)Sven Benson (Founder, candidum)Mark Whittaker (Senior Vice President, Evotec)Edelmiro Moman (Scientific Consultant and Teacher, ProSciens) To request sample pages, please visit this link Key Questions AnsweredWho are the leading in silico service providers for discovery of different types of large molecule drugs?What are the key challenges associated with the discovery of large molecule drugs?What is the likely cost saving opportunity associated with the use of in silico tools?What are the key computational approaches being used by in silico service providers for drug discovery operations?What are the popular business strategies being used by in silico drug discovery service providers?How is the current and future market opportunity likely to be distributed across key market segments?You may also be interested in the following titles:DNA-Encoded Libraries: Platforms and Services MarketGlobal Stem Cells Market: Focus on Clinical Therapies, 2020–2030Companion Diagnostics Services Market, 2020-2030 Contact UsGaurav Chaudhary+1 (415) 800 [email protected]
1
Excessive capital requirement and myriad of other complexities associated with the discovery of biologics have prompted drug developers to adopt in silico tools / techniques to expedite the discovery timelines Roots Analysis is pleased to announce the publication of its recent study, titled, “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches).” The  report features an extensive study on the current landscape and the likely future potential of the companies offering services for the discovery of large molecule drugs based on the use of in silico tools and techniques.The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders.In addition to other elements, the report includes:A detailed assessment of the current market landscape of companies offering in silico drug discovery services for large molecules.Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services (shortlisted on the basis of the company size).A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters related to company and services.An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.A detailed analysis assessing the current opportunity within in silico drug discovery services market.A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry.An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.A case study comparing the key challenges associated with the discovery and production of large molecules.Insights from an industry-wide survey, featuring inputs solicited from various experts in this domain.A discussion on the upcoming computational approaches that are being adopted for drug discovery purposes.A case study highlighting several non-computational methods / technologies used in drug discovery process.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Key Drug Discovery StepsTarget IdentificationTarget ValidationHit GenerationHit-to-LeadLead Optimization Type of Large MoleculeAntibodiesProteinsPeptidesNucleic AcidsVectors Company SizeSmallMid-sizedLarge Target therapeutic AreaAutoimmune DisordersBlood DisordersCardiovascular DisordersGastrointestinal and Digestive DisordersHormonal DisordersHuman Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)Infectious DiseasesMetabolic DisordersMental DisordersMusculoskeletal DisordersNeurological DisordersOncological DisordersRespiratory DisordersSkin DisordersUrogenital DisordersOthers Type of SponsorIndustry PlayersNon-Industry Players Key Geographical RegionsNorth AmericaEuropeAsia-Pacific Transcripts of interviews held with the following senior level representatives of stakeholder companiesJohn L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals)Sven Benson (Founder, candidum)Mark Whittaker (Senior Vice President, Evotec)Edelmiro Moman (Scientific Consultant and Teacher, ProSciens) Key companies covered in the reportAbzenaBioDuroBioNTechChemPartnerCreative BiostructureGenScriptLakePharmaSundia MediTechSygnature DiscoveryViva Biotech For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html Other Recent OfferingsDNA-Encoded Libraries: Platforms and Services MarketGlobal Stem Cells Market: Focus on Clinical Therapies, 2020–2030Companion Diagnostics Services Market, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]  
To order this detailed 640+ page report, please visit this link Key InclusionsA detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designations (if any).In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics (which are presently in both preclinical and clinical stages of development); each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook.A discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with [A] a detailed review of the current market landscape of microbiome diagnostic tests, including the information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis, [B] brief profiles of popular diagnostic developers, and [C] an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time.A review of the historical evolution and other relevant aspects of FMT therapies, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with [A] a detailed assessment of the current market landscape of FMT therapies, providing information on FMT developer(s) (such as year of establishment, location of headquarters and company size), status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration, [B] a geographical clinical trial analysis of ongoing / planned / completed studies of FMTs sponsored by non-industry players, featuring details related to specific FMT therapies and analysis based on relevant parameters, such as the number of registered trials, year of registration, current status, phase of development, study design, type of sponsor(s), target indication(s), key therapeutic area(s), key focus areas, number of patients enrolled and leading non-industry player(s), and [C] information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.
The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine.Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator.However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this link The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:Type of Therapy (Tx)Prescription DrugPrebioticsProbiotics Type of Molecule (Tx)Small MoleculesBiologics Target Indication (Tx+Dx)Acne VulgarisAtopic DermatitisClostridium difficile InfectionColorectal CancerCrohn’s DiseaseDiabetesIrritable Bowel SyndromeLactose IntoleranceLung CancerNonalcoholic steatohepatitis (NASH)ObesityUlcerative colitis Therapeutic Area (Tx+Dx)Autoimmune DisordersDental DisordersDigestive and Gastrointestinal DisordersDermatological DisordersInfectious DiseaseMetabolic DisordersOncologyOthers Key Geographical Regions (Tx+Dx)North AmericaEuropeAsia-Pacific and Rest of the World  The Human Microbiome Market, 2019-2030 report features the following companies, which we identified to be key players in this domain: 4D PharmaArmata PharmaceuticalsEvelo BiosciencesRebiotix (Acquired by Ferring Pharmaceuticals)Seres TherapeuticsVedanta Biosciences Table of ContentsPreface Executive Summary Introduction Microbiome Therapeutics: Market Landscape Company and Drug Profiles Microbiome Diagnostics: Market Landscape Fecal Microbiota Therapy (FMT) Attractiveness Competitiveness (AC) Matrix Microbiome Related Initiatives of Big Pharmaceutical Players Start-up Health Indexing Key Therapeutics Areas Funding and Investment Analysis Contract Services for Microbiome Therapeutics Big Data and Microbiome Therapeutics Microbiome Therapeutics: Market Forecast and Opportunity Analysis Microbiome Diagnostics: Market Forecast and Opportunity Analysis Fecal Microbiota Therapies: Market Forecast and Opportunity Analysis Case Study: Microbiome-based Products in Other Industries Concluding Remarks Executive Insights Appendix I: Tabulated Data Appendix II: List of Companies and Organizations  To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]  
Over the years, extensive R efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.In addition to other elements, the study includes:A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s).Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics.A detailed review of the current market landscape of microbiome diagnostic tests, brief profiles of popular diagnostic developers and indicative list of screening and profiling test kits.A detailed assessment of the current market landscape of FMT therapies, a geographical clinical trial analysis and information on various stool banks.A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework.An analysis of the varied microbiome-focused initiatives of big pharma players.An analysis of the start-ups / small-sized players engaged in the development of microbiome therapeutics and diagnostics.An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs.An analysis of the investments made at various stages of development in start-ups / small-sized companies.An indicative list of contract manufacturers, in-house manufacturers and CROs that currently claim to have the necessary capabilities.An assessment of the emerging role of big data highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from in the microbiome research.An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food productsA detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)segments:Type of Therapy (Tx)Prescription DrugPrebioticsProbiotics                   Type of Molecule (Tx)Small MoleculesBiologics Target Indication (Tx+Dx)Acne VulgarisAtopic DermatitisClostridium difficile InfectionColorectal CancerCrohn’s DiseaseDiabetesIrritable Bowel SyndromeLactose IntoleranceLung CancerNonalcoholic steatohepatitis (NASH)ObesityUlcerative colitis Therapeutic Area (Tx+Dx)Autoimmune DisordersDental DisordersDigestive and Gastrointestinal DisordersDermatological DisordersInfectious DiseaseMetabolic DisordersOncologyOthers Key Geographical Regions (Tx+Dx)North AmericaEuropeAsia-Pacific and Rest of the World Key companies covered in the report4D PharmaArmata PharmaceuticalsEvelo BiosciencesRebiotix (Acquired by Ferring Pharmaceuticals)Seres TherapeuticsVedanta Biosciences For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email [email protected] Other Recent Offerings:Antibody Drug Conjugates Market (5th Edition), 2019-2030Gene Therapy Market (3rd Edition), 2019 - 2030Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030Synthetic Lethality-based Drugs and Targets Market, 2019-2030  About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]
1
Active Pharmaceutical Ingredients Market OverviewThe global active pharmaceutical ingredients market is witnessing a massive rise amid COVID 19 outbreak.Active pharmaceutical ingredients (API) are the main ingredient in a number of drugs that are intended for the treatment of COVID 19.Moreover, the increasing numbers of healthcare infrastructure, including hospitals & clinics, are expected to foster market growth.Additionally, factors such as the growing healthcare expenditures and the increase in the global population & economy positively impact the growth of the API market.Conversely, adverse effects associated with API and the availability of substitutes are the major factors anticipated to restrain the growth of the market.In addition, the shortage of particular APIs required in human drugs indicated for coronavirus treatment is posing challenges to market growth.Global Active Pharmaceutical Ingredients Market – SegmentsThe report is segmented into six dynamics;By Manufacturing Process: Captive Manufacturing, Contract Manufacturing, and others.By Type of Synthesis: Synthetic, Biotech, and others.By API Formulation: Generic API, Branded/ Innovative API, and others.By Application: Oncology, Cardiovascular Disease, Neurological Disorders, Orthopedic Disorders, Respiratory, Gastrointestinal Disorders, Urology, and others.By Molecule: Large Molecule, Small Molecule, and others.By Regions: Americas, Europe, Asia Pacific, and the rest-of-the-world.Global Active Pharmaceutical Ingredients Market – Geographical AnalysisNorth America leads the global active pharmaceutical ingredients market.The region’s largest market share attributes to the rising prevalence of myriads of chronic diseases such as cardiovascular & neurological diseases and orthopedic, respiratory, and gastrointestinal disorders.
Growth in this market is driven majorly by the rising R spending in the pharmaceutical & biopharmaceutical industry, growing demand for membrane filtration technology, increasing purity requirements in end-user segments, and growing focus on developing large-molecule biopharmaceuticals.Laboratory filtration market size is projected to reach USD 4.1 billion by 2025 from USD 2.5 billion in 2019, at a CAGR of 8.3% during the forecast period.Laboratory filtration market by Product (Filtration Assembly, Filter Media Accessories), Technology (Ultrafiltration, Microfiltration, Nanofiltration, RO), End User (Pharmaceutical, Biopharmaceutical Company, F), Region.The study involved four major activities in estimating the current size of the laboratory filtration market.Exhaustive secondary research was conducted to collect information on the market as well as its peer and parent markets.The next step was to validate these findings, assumptions, and sizes with industry experts across the value chain through primary research.Ask for FREE PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12936082The filtration media segment accounted for the largest share of the market, by product, in 2018Based on product, the market is segmented into filtration media (filter papers, membrane filters, syringe and syringeless filters, filtration microplates, and other filtration media), filtration assemblies (microfiltration assemblies, reverse osmosis assemblies, ultrafiltration assemblies, vacuum filtration assemblies, and other filtration assemblies), and filtration accessories (filter holders, filter funnels, filter flasks, membrane dispensers, filter housings, cartridges, vacuum pumps, seals, and other filtration accessories).The microfiltration segment accounted for the largest share of the market, by technique, in 2018Based on technique, the market is segmented into microfiltration, ultrafiltration, reverse osmosis, vacuum filtration, and nanofiltration.The microfiltration segment accounted for the largest share in 2018, while the ultrafiltration segment is projected to witness the highest growth during the forecast period.Rising R activities in the pharma industry and wide applications in the food & beverage industry are the key factors boosting the growth of this market segment.Region Covered in Laboratory Filtration Market :The global lab filtration market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
1
 To order this detailed 300+ page report, please visit this link Key InclusionsA detailed review of the overall landscape of companies offering contract services for the manufacturing of HPAPIs and cytotoxic drugs, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number and location of manufacturing facilities, facility size, type of service(s) offered (clinical manufacturing, commercial manufacturing, analytical testing, scale-up, process development / pre-formulation, formulation development, stability studies, regulatory support and fill / finish and packaging), type of product manufactured (HPAPIs and highly potent finished dosage forms), type of pharmacological molecule (biologics and small molecules), type of highly potent finished dosage form manufactured (capsules, granules, injectables, liquids and tablets), and type of primary packaging used (ampoules, blisters, prefilled syringes, conventional syringes, vials and others).A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, taking into consideration supplier strength (based on company size and its experience in this field) and service strength (based on scale of operation, type of service(s) offered, type of product(s) manufactured, number and location of manufacturing facilities, type of highly potent finished dosage forms manufactured and type of primary packaging used).Elaborate profiles of the key players (shortlisted based on a proprietary criterion) that offer a diverse range of capabilities for the development, manufacturing and packaging of HPAPIs and cytotoxic drugs, across North America, Europe and Asia Pacific.Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available).In addition to this, the profile includes information on the various HPAPIs / cytotoxic dugs manufacturing services offered by the company, along with the location of their manufacturing facilities.Further, we have provided the recent developments of the company and an informed future outlook.An analysis of the various partnerships pertaining to the contract manufacturing of HPAPIs and cytotoxic drugs, which have been established since 2014, based on several parameters, such as the year of partnership, type of partnership, type of product, scale of operation, company size, amount invested in acquisitions, most active player and geographical analysis.An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective HPAPI and cytotoxic drug manufacturing capabilities, over the period 2014-2019, taking into consideration several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), scale of operation (preclinical, clinical and commercial), type of product manufactured (HPAPIs and highly potent finished dosage forms), and location of manufacturing facility.An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain; it highlights the distribution of available HPAPIs and cytotoxic drugs production capacity on the basis of company size (small-sized, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial), and across key geographical regions (North America, Europe, Asia Pacific and rest of the world).A qualitative analysis, highlighting the various factors that need to be taken into consideration by highly potent drug developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers that are currently active in this space.Additionally, it includes a detailed set of analyses of these companies based on several parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number and location of manufacturing facilities, and type of service(s) offered.The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:Type of ProductHPAPIsHighly Potent Finished Dosage Forms Company SizeSmall-sizedMid-sizedLarge / Very Large Scale of OperationPreclinical / ClinicalCommercial Type of Pharmacological MoleculeSmall MoleculesBiologics Type of Highly Potent Finished Dosage FormInjectablesOral SolidsCreamsOthers Key geographical regionsNorth AmericaEuropeAsia PacificRest of the World To request sample pages, please visit this link Key Questions AnsweredWho are the key manufacturers of HPAPIs and cytotoxic drugs, across the world?What kind of partnership models are commonly adopted by stakeholders in this domain?What is the current, installed contract manufacturing capacity for HPAPIs?What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to HPAPIs and cytotoxic drugs?What are the key drivers and growth constraints in HPAPI and cytotoxic drugs manufacturing market?How is the current and future market opportunity likely to be distributed across key market segments?
Roots Analysis has done a detailed study on High Energy Chemistry / Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature / Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.To order this 240+ page report, which features 90+ figures and 100+ tables, please visit this link Key Market Insights Presently, over 100 service providers across the globe have capabilities to handle high energy / hazardous chemistry conditions, offering contract and custom manufacturing services for pharmaceutical APIsThe market landscape is highly fragmented, featuring the presence of both established players and new entrants; majority of the companies have presence in Europe and Asia Pacific regionsAPI manufacturing facilities of service providers are well equipped to handle / maintain a wide range of temperature and pressure conditions to carry out HEC reactionsIndustry stakeholders are actively expanding their existing capabilities through installation of advanced equipment at their manufacturing facilities, in order to maintain a competitive edge in the marketService Providers are offering a diverse portfolio of reactions for manufacturing of synthetic APIs; Hydrogenation and Grignard reactions are the most popular types of reactions offered by playersCase In Point: Contract research service providers cater to the needs related to process development and small scale synthesis of APIs based on HEC / hazardous chemistryIn the long-term, the projected opportunity is anticipated to be worth USD 29 billion by 2030; the opportunity is anticipated to be well distributed across companies of varying sizes, scale of operation and geographies For more information, please visit https://www.rootsanalysis.com/reports/high-energy-chemistry.html Table of Contents  PREFACE1.1.Analysis by Location of Manufacturing Facilities           5.2.6.Regional Capability Assessment Summary  COMPANY COMPETITIVENESS ANALYSIS7.1.Analysis by Less Popular Reactions9.2.3.1.HEC-based API Manufacturing Services Market in Asia Pacific11.4.4.
Although hazardous reaction chemistries are not used during early drug development stages owing to the associated risks, they offer a wide range of benefits over traditional approaches, especially from the perspective of large-scale manufacturing Roots Analysis is pleased to announce the publication of its recent study, titled, “High Energy Chemistry / Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature / Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030.” The report features an extensive study on the current landscape and the likely future potential of the companies offering services for API manufacturing based on high energy chemistry (HEC) / hazardous chemistry.The study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders.In addition to other elements, the study includes:A detailed assessment of the current market landscape of service providers offering contract and custom services for HEC / hazardous chemistry-based API manufacturing.A detailed list of around 150 manufacturing facilities equipped to handle API manufacturing under high temperature, low temperature, high pressure and low pressure conditions.A competitiveness 3-D bubble analysis of HEC / hazardous chemistry-based contract and custom manufacturersElaborate profiles of the key players that offer a diverse range of capabilities for API manufacturing based on HEC / hazardous chemistry.A qualitative case study providing insights on the general reaction portfolio related to small molecule synthesis processes.A detailed case study presenting a list of contract research organizations (CROs) and custom synthesis service providers engaged in this domain.A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Reaction Conditions High TemperatureLow TemperatureHigh PressureLow PressureKey Geographical Region North AmericaEuropeAsia-Pacific and the Rest of the World  The report features inputs from the following eminent industry stakeholders, according to whom, as more companies become aware of the benefits of exploiting novel synthetic routes, via hazardous reaction chemistries, for drug development, the demand for HEC-based manufacturing services may be anticipated to increase in the coming years.Eric Fang, Chief Scientific Officer, Snapdragon ChemistryAnonymous, NovasepEdward Price, President / Chief Executive Director, PCI Synthesis Key companies covered in the reportAGC ChemicalsBeijing Mediking BiopharmCambrexCordenPharmaEvonik IndustriesHovionePatheonPCI SynthesisSiegfried For more information please click on the following link:https://www.rootsanalysis.com/reports/high-energy-chemistry.html Other Recent OfferingsChina Pharmaceutical Contract Manufacturing Services Market, 2020-2030Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected] 
1
More

Top